There is no single best treatment for multiple sclerosis. The right choice depends on the type of MS you have, how active your disease is, your tolerance for risk, and how you feel about needles, infusions, or daily pills. What research does make clear is that starting an effective treatment early, before significant damage accumulates, leads to dramatically better outcomes than waiting.
More than 20 disease-modifying therapies are now approved for MS, and they vary widely in how well they work, how they’re taken, and what side effects they carry. Here’s what you need to know to have an informed conversation with your neurologist.
Why Starting Strong and Early Matters
For years, the standard approach was to begin with a milder, lower-risk medication and escalate to stronger options only if the disease broke through. That thinking has shifted. A study published in Multiple Sclerosis and Related Disorders compared patients who started on high-efficacy therapies right away against those who followed the traditional escalation approach. The results were striking: patients who started strong had a 70% lower risk of relapse, 77% less new disease activity on MRI, and were 67% less likely to need a treatment switch.
This doesn’t mean every person with MS should be on the most powerful drug available. But it does mean the old instinct to “save the big guns for later” often costs people brain tissue they can’t get back. Many neurologists now recommend high-efficacy treatment from the start, especially for people with active inflammation or signs of aggressive disease.
High-Efficacy Therapies
The therapies with the strongest evidence for controlling MS fall into a few categories, and they differ mainly in how they’re delivered and what risks they carry.
Anti-CD20 Therapies (B-Cell Depletion)
These work by wiping out a specific type of immune cell that drives MS inflammation. They are among the most effective options available and have become a go-to choice for many neurologists. Ocrelizumab is given as an intravenous infusion every six months. Ublituximab follows a similar schedule. Ofatumumab is a monthly injection you can give yourself at home with a prefilled pen, which appeals to people who want to avoid infusion centers. All three produce deep suppression of disease activity. Ocrelizumab is also the only approved therapy for primary progressive MS, making it uniquely important for that population.
Natalizumab
This infusion, given every four weeks, is one of the most potent options for relapsing MS. It works by blocking immune cells from crossing into the brain and spinal cord. The trade-off is a rare but serious brain infection called PML. Your risk depends largely on whether you carry a common virus called JC virus. If your JC virus antibody index is below 0.9, the risk can be lower than 1 in 3,300. If the index is high and you’ve been on the drug for over two years, that risk can climb to as high as 1 in 33 in the worst-case scenario. Regular blood monitoring helps manage this, and many people use natalizumab safely for years, but it requires close attention.
Alemtuzumab
This is the closest thing to a “reset button” for the immune system. It’s given as a series of infusions over five days, then again for three days one year later. Some people need no further treatment after that. The potency comes with significant monitoring requirements, including monthly blood and urine tests for years afterward to catch autoimmune side effects early.
Oral Treatments
If taking a pill every day sounds more manageable than infusions or injections, several oral therapies are available. They generally fall in the moderate-efficacy range, though some are quite effective for the right patient.
A group of drugs that modulate a receptor involved in immune cell trafficking (fingolimod, ozanimod, ponesimod, and siponimod) are taken as a daily pill. They keep certain immune cells locked in the lymph nodes so they can’t attack the nervous system. These require a heart monitoring session when you take the first dose, since they can temporarily slow your heart rate. Siponimod is specifically approved for secondary progressive MS with active inflammation, filling an important gap.
Fumarate-based pills (dimethyl fumarate, diroximel fumarate, and monomethyl fumarate) are taken twice daily and work through anti-inflammatory and protective mechanisms. They’re generally well tolerated, though flushing and stomach discomfort are common early on. Diroximel fumarate was designed to reduce those GI side effects.
Teriflunomide is a once-daily pill with a more modest effect on relapse rates. It’s sometimes chosen for people with milder disease or those who prioritize a simpler safety profile.
Cladribine takes a different approach entirely. You take short courses of pills over two years, and then you’re done. It works by selectively depleting the immune cells driving your MS, and the effect lasts well beyond the treatment period. It’s considered high-efficacy but is typically reserved for people who haven’t responded to other therapies.
Injectable Therapies
The interferons and glatiramer acetate were the first MS therapies approved and are still used today, though less frequently now that stronger options exist. They reduce relapse rates by roughly 30%, which is meaningful but modest compared to newer drugs. Injection frequency ranges from every other day to every two weeks, depending on the specific product. Peginterferon beta-1a, the newest interferon, only requires an injection every 14 days.
These older therapies have decades of safety data behind them, which matters to some patients. They’re reasonable for people with very mild disease who want minimal risk, but for most people with active MS, the newer therapies offer substantially better disease control.
Treatment for Primary Progressive MS
Primary progressive MS, where disability worsens gradually from the start without clear relapses, has far fewer treatment options. Ocrelizumab is currently the only approved therapy. In clinical trials, it modestly slowed the accumulation of disability compared to placebo, particularly in younger patients with signs of ongoing inflammation on MRI. For many people with PPMS, treatment focuses heavily on rehabilitation, physical therapy, and managing specific symptoms alongside ocrelizumab.
Managing Relapses
Even on a disease-modifying therapy, relapses can still happen. When they cause significant new symptoms, the standard treatment is a course of high-dose corticosteroids given intravenously over three to five days. This doesn’t change the long-term course of MS, but it shortens the duration of the relapse and speeds recovery. If intravenous treatment isn’t practical, high-dose oral steroids can be substituted. Not every relapse needs steroid treatment. Mild sensory symptoms that don’t interfere with daily function often resolve on their own.
Symptom Management Beyond DMTs
Disease-modifying therapies target the underlying immune attack, but they don’t directly treat the symptoms MS causes day to day. Fatigue, spasticity, bladder problems, pain, walking difficulty, and cognitive fog each have their own management strategies. Physical therapy and exercise are consistently among the most effective interventions for fatigue and mobility. Cooling strategies help people whose symptoms worsen with heat. Pelvic floor therapy can improve bladder control. Cognitive rehabilitation helps with thinking and memory issues.
For many people living with MS, the combination of the right disease-modifying therapy and a personalized symptom management plan makes a bigger difference than either approach alone. The “best” treatment is the one that controls your disease activity, fits your life, and carries risks you’re comfortable with, and that calculation is genuinely different for every person.